Prostate cancer treatment – China's perspective

Liu, Jiazhou; Dong, Liang; Zhu, Yao; Dong, Baijun; Sha, Jianjun; Zhu, Helen He; Pan, Jiahua; Xue, Wei

doi:10.1016/j.canlet.2022.215927

Cited by 35 publications

(20 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coinciding with these ndings, a pooled analysis of 17 tumor registries in China revealed that the overall age-standardized 5-year relative survival rate for PCa was 66.4% during 2012-2015, exhibiting an incremental 3.8% increase every three years since 2003 21,22 . The increase in crude mortality rate could be attributed to China's status as the most populous country in the world, coupled with a signi cant degree of population aging.…”

Section: Discussionmentioning

confidence: 83%

“…Postoperative combined with androgen blockade therapy for radical prostatectomy demonstrated a 2-year PSA recurrence rate of 15.2%, with a signi cant improvement in quality of life 21 . The concept of the Multi-disciplinary Team (MDT) has gained broad acceptance within medical institutions throughout our nation 22 . It can optimize specialty strengths, delivering comprehensive, personalized care, and thereby improving diagnostic and treatment effectiveness.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prostate cancer mortality time trends in BRICS, from 1990 to 2019: an age- period-cohort analysis for the Global Burden of Disease 2019

Feng,

He,

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Currently, Prostate cancer contributes to a growing disease burden. However, limited research has assessed Prostate cancer trends in Brazil, Russia, India, China, and South Africa (BRICS). The objective is to report the trends in Prostate cancer mortality across BRICS from 1990 to 2019, along with the age-period-cohort effects. Methods The relevant data was sourced from the Global Burden of Disease Study 2019 and an age-period-cohort model was used to calculate net drifts (overall annual percentage change), local drifts (annual percentage change in each age group), longitudinal age curves (expected longitudinal age-specific rate), and period (cohort) relative risks. Results In 2019, the global mortality of Prostate cancer increased by 108.94% compared to 1990; but the age-standardized mortality rate has decreased by 9.46%. Between 1990 and 2019, India experienced the greatest reduction in age-standardized mortality rate. South Africa and Russia have experienced an increase in age-standardized mortality rate. The mortality rate of Prostate cancer increased with advancing age. The period and cohort risks of Prostate cancer mortality have generally shown improvement across BRICS. However, the temporal effect in the later periods for Russia is not significant, and the cohort risk of Prostate cancer mortality for the Brazilian cohort born in the 1980s is higher. Conclusions The BRICS have achieved commendable progress in controlling Prostate cancer mortality. However, the disease burden of Prostate cancer remains substantial in BRICS. The Prostate cancer mortality vary significantly among these countries; therefore, it is advisable for BRICS to formulate effective policies based on their national circumstances.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Prostate cancer mortality time trends in BRICS, from 1990 to 2019: an age- period-cohort analysis for the Global Burden of Disease 2019

Feng,

He,

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Prostate cancer (PCa) is one of the most common cancers for male ( Sung et al, 2021 ; Liu et al, 2022 ). PSMA is the most attractive of prostate antigen, which is highly expressed in prostate epithelial cells ( Ceci et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

“…Globally, prostate cancer (PCa) is the second most common cancer type in men and the fifth leading cause of cancer-related death worldwide ( Sung et al, 2021 ; Liu et al, 2022 ). Although most PCa is indolent or extremely slowly progressing, approximately 20% of patients are diagnosed with the fatal high-risk form, life-threatening ( Chang et al, 2014 ; Adamaki and Zoumpourlis, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Laser-activated nanoparticles for ultrasound/photoacoustic imaging-guided prostate cancer treatment

Xiao

Dai

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignant tumor in men. Prostate-specific membrane antigen (PSMA), which is overexpressed on the surface of Prostate cancer cells, may serve as a potential therapeutic target. Recently, image-guided and targeted therapy for prostate cancers has attracted much attention by using Prostate-specific membrane antigen targeting nanoparticle. In this study, we produced PSMA-targeted light-responsive nanosystems. These nanosystems of liquid perfluorocarbon cores and polymer shells were loaded with the photosensitizer IR780 and therapeutic drugs paclitaxel. The liquid perfluorocarbon (PFP) in nanoparticles can perform ultrasound-enhanced imaging by liquid-gas transition and promote the deliver and release of paclitaxel. IR780 can perform photothermal therapy (PTT) guided by photoacoustic (PA) imaging. Combination treatment with photothermal therapy and chemotherapy exhibited excellent inhibition of cell proliferation in vitro and a significant therapeutic effect in vivo. In conclusion, we successfully formulated PSMA-targeted nanosystems with precision targeting and ultrasound/PA dual-modality imaging for anti-tumor effects.

show abstract

“…However, these research objects were mainly localized PCa treated with RP and/or RT. In actual clinical work, many cancers are diagnosed in advanced stages 9 . Considering factors such as the disease status, the patients’ intentions and social economics, many patients may only receive hormonal therapy (HT).…”

Section: Introductionmentioning

confidence: 99%

Investigation of radiomics models for predicting biochemical recurrence of advanced prostate cancer on pretreatment MR ADC maps based on automatic image segmentation

Wang,

et al. 2023

J Applied Clin Med Phys

View full text Add to dashboard Cite

ObjectivesTo develop radiomics models based on automatic segmentation of the pretreatment apparent diffusion coefficient (ADC) maps for predicting the biochemical recurrence (BCR) of advanced prostate cancer (PCa).MethodsA total of 100 cases with pathologically confirmed PCa were retrospectively included in this study. These cases were randomly divided into training (n = 70) and test (n = 30) datasets. Two predictive models were constructed based on the combination of age, prostate specific antigen (PSA) level, Gleason score, and clinical staging before therapy and the prostate area (Model_1) or PCa area (Model_2). Another two predictive models were constructed based on only prostate area (Model_3) or PCa area (Model_4). The area under the receiver operating characteristic curve (ROC AUC) and precision‐recall (PR) curve analysis were used to analyze the models’ performance.ResultsSixty‐five patients without BCR (BCR−) and 35 patients with BCR (BCR+) were confirmed. The age, PSA, volume, diameter and ADC value of the prostate and PCa were not significantly different between the BCR− and BCR+ groups or between the training and test datasets (all p > 0.05). The AUCs were 0.637 (95% CI: 0.434–0.838), 0.841 (95% CI: 0.695–0.940), 0.840 (95% CI: 0.698–0.983), and 0.808 (95% CI: 0.627–0.988) for Model_1 to Model_4 in the test dataset without significant difference. The 95% bootstrap confidence intervals for the areas under the PR curve of the four models were not statistically different.ConclusionThe radiomics models based on automatically segmented prostate and PCa areas on the pretreatment ADC maps developed in our study can be promising in predicting BCR of advanced PCa.

show abstract

Prostate cancer treatment – China's perspective

Cited by 35 publications

References 145 publications

Prostate cancer mortality time trends in BRICS, from 1990 to 2019: an age- period-cohort analysis for the Global Burden of Disease 2019

Prostate cancer mortality time trends in BRICS, from 1990 to 2019: an age- period-cohort analysis for the Global Burden of Disease 2019

Laser-activated nanoparticles for ultrasound/photoacoustic imaging-guided prostate cancer treatment

Investigation of radiomics models for predicting biochemical recurrence of advanced prostate cancer on pretreatment MR ADC maps based on automatic image segmentation

Contact Info

Product

Resources

About